Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in Clin Ther

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    November 2020
  1. KANTOR D, Mehta R, Pelletier C, Tian M, et al
    Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Clin Ther. 2020 Nov 4. pii: S0149-2918(20)30464.
    PubMed     Abstract available


    June 2020
  2. DESLANDES MQ, Alves PT, Alvarenga MP, Lessa VCC, et al
    Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis.
    Clin Ther. 2020 Jun 24. pii: S0149-2918(20)30241.
    PubMed     Abstract available


    April 2020
  3. SANCHEZ MARTINEZ I, Cerdan Sanchez M, Lopez Roman J, Iniesta Martinez F, et al
    Possible Influence of the Route of Treatment Administration on Treatment Adherence in Patients With Multiple Sclerosis.
    Clin Ther. 2020 Apr 30. pii: S0149-2918(20)30132.
    PubMed     Abstract available


    December 2019
  4. SPELMAN T, Freilich J, Anell B, Wong SL, et al
    Patients with High-Disease-Activity Relapsing-Remitting Multiple Sclerosis in Real-World Clinical Practice: A Population-Based Study in Sweden.
    Clin Ther. 2019 Dec 31. pii: S0149-2918(19)30587.
    PubMed     Abstract available


    June 2019
  5. KRESA-REAHL K, Repovic P, Robertson D, Okwuokenye M, et al
    Corrigendum to "Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study" [Clinical Therape
    Clin Ther. 2019 Jun 26. pii: S0149-2918(19)30297.
    PubMed    


    May 2019
  6. REN J, Ascencio M, Raimondi T, Rainville EC, et al
    Association Between Exposure of Ipratropium and Salmeterol and Diagnosis of Multiple Sclerosis: A Matched Case-control Study.
    Clin Ther. 2019 May 22. pii: S0149-2918(19)30242.
    PubMed     Abstract available


    February 2019
  7. VERMERSCH P, Martinelli V, Pfleger C, Rieckmann P, et al
    Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Clin Ther. 2019;41:249-260.
    PubMed     Abstract available


    November 2018
  8. KRESA-REAHL K, Repovic P, Robertson D, Okwuokenye M, et al
    Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-Reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
    Clin Ther. 2018 Nov 20. pii: S0149-2918(18)30506.
    PubMed     Abstract available


    May 2018
  9. VISARIA J, Thomas N, Gu T, Singer J, et al
    Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice.
    Clin Ther. 2018 May 23. pii: S0149-2918(18)30186.
    PubMed     Abstract available


    March 2018
  10. KITA M, Fox RJ, Gold R, Giovannoni G, et al
    Corrigendum to 'Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (
    Clin Ther. 2018 Mar 7. pii: S0149-2918(18)30055.
    PubMed    


    December 2017
  11. MOTL RW, Sandroff BM
    Exercise as a Countermeasure to Declining Central Nervous System Function in Multiple Sclerosis.
    Clin Ther. 2017 Dec 26. pii: S0149-2918(17)31106.
    PubMed     Abstract available


    July 2017
  12. FERNANDEZ O, Giovannoni G, Fox RJ, Gold R, et al
    Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Clin Ther. 2017 Jul 24. pii: S0149-2918(17)30765.
    PubMed     Abstract available


    February 2017
  13. SOINI E, Joutseno J, Sumelahti ML
    Cost-Utility of First-Line Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Clin Ther. 2017 Feb 13. pii: S0149-2918(17)30074.
    PubMed     Abstract available


  14. VAN AMERONGEN G, Kanhai K, Baakman AC, Heuberger J, et al
    Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Delta9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis.
    Clin Ther. 2017 Feb 9. pii: S0149-2918(17)30054.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: